# US 9,753,030 B2 · Degradable carbon nanotube-containing biosensors and methods for target clinical marker detection > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 9,753,030 B2 - Document ID: US9753030B2 - Status: Granted - Kind: B2 - Application number: 14/197,722 - Filed: 2014-03-05 - Published: 2014-09-11 - Granted: 2017-09-05 - Earliest claimed: 2013-03-06 - Assignees: University of Pittsburgh—Of the Commonwealth System of Higher Education - Applicants: University of Pittsburgh—of the Commonwealth System of Higher Education - Inventors: Prashant Nagesh Kumta; Madhumati Ramanathan; Mitali Shirish Patil - Web page: https://patentgrep.com/patent/US9753030B2 ## CPC - A61B 5/14503: {invasive, e.g. introduced into the body by a catheter or needle or using implanted sensors (A61B5/1459, A61B5/1464, A61B5/1473, A61B5/1482, A61B5/14865 take precedence)} - G01N 33/54373: {involving physiochemical end-point determination, e.g. wave-guides, FETS, gratings} - A61B 5/053: Measuring electrical impedance or conductance of a portion of the body - A61B 5/14546: {for measuring analytes not otherwise provided for, e.g. ions, cytochromes} - A61B 5/14735: {comprising an immobilised reagent} - A61B 5/4504: {Bones (A61B5/4547 takes precedence)} - C12Q 1/42: involving phosphatase - A61B 2562/0285: Nanoscale sensors - A61B 2562/0295: Strip shaped analyte sensors for apparatus classified in A61B5/145 or A61B5/157 - A61B 2562/12: Manufacturing methods specially adapted for producing sensors for in-vivo measurements - B82Y 15/00: Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors - Y10S 977/748: Modified with atoms or molecules bonded to the surface - Y10S 977/92: Detection of biochemical - A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D) - G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q) - C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES - B82Y: SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES - Y10S: TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS ## Abstract The invention relates to carbon nanotube-containing composites as biosensors to detect the presence of target clinical markers, methods of their preparation and uses in the medical field. The invention is particularly suitable for the detection in patient biological specimens of bone markers and tissue markers. The biosensors of the invention include carbon nanotubes deposited on a substrate, gold nanoparticles deposited on the carbon nanotubes and, binder material and biomolecule deposited on the gold-coated carbon nanotubes. The biomolecule is selected to interact with the target clinical markers. The biosensor can be used as an in-situ or an ex-situ device to detect and measure the presence of the target clinical markers. ## Claims ### Claim 1 A degradable biosensor composite, comprising: an implant device; a plurality of carbon nanotubes having an outer surface and deposited on the implant device; a plurality of gold nanoparticles electrodeposited on the outer surface of the plurality of carbon nanotubes to form gold-coated nanotubes; a binding material adsorbed on the plurality of gold nanoparticles; and a biotinylated biomolecule selected to bind with the binding material and interact with a target clinical marker selected from the group consisting of c-terminal telopeptide, n-terminal telopeptide, alkaline phosphatase, Troponin I and myoglobin, wherein, the degradable biosensor composite is effective to detect bone and/or tissue resorption, depending on selection of the target clinical marker, in a patient body resulting from the implant device. ### Claim 2 (depends on 1) The biosensor of claim 1, wherein the biotinylated biomolecule is selected from the group consisting of antibody and aptamer. ### Claim 3 (depends on 1) The biosensor of claim 1, wherein the biotinylated biomolecule is selected from the group consisting of c-terminal telopeptide antibody, n-terminal telopeptide antibody, alkaline phosphatase antibody, Troponin I antibody and myoglobin antibody. ### Claim 4 (depends on 1) The biosensor of claim 1, wherein the biotinylated biomolecule is aptamer selected specifically for the target clinical marker. ### Claim 5 (depends on 1) The biosensor composite of claim 1, wherein the implant device is a degradable scaffold. ### Claim 6 (depends on 5) The biosensor composite of claim 5, wherein the degradable scaffold is composed of a magnesium alloy. ### Claim 7 (depends on 1) The biosensor composite of claim 1, wherein the implant device comprises a substrate of a non-conducting material for receiving the carbon nanotubes. ### Claim 8 (depends on 7) The biosensor composite of claim 7, wherein the implant device is a degradable scaffold. ### Claim 9 (depends on 8) The biosensor composite of claim 8, wherein the degradable scaffold is composed of a magnesium alloy. ### Claim 10 (depends on 1) The biosensor composite of claim 1, wherein the binding material is selected from the group consisting of avidin, neutravidin and mixtures thereof. ### Claim 11 (depends on 7) The biosensor composite of claim 7, wherein the substrate is selected from the group consisting of silicon and silicon containing materials.